2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
Avatar

2020 ASCO Update on HER2+ MBC: Comparing Efficacy of HER2 Kinase Inhibitors vs. Antibody Drug Conjugates vs. Immunomodulatory Agents

By 2020 ASCO Virtual Direct™ Highlights FEATURING Ian Krop
By 2020 ASCO Virtual Direct™ Highlights FEATURING Ian Krop
562 views
July 13, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

20:00
Exelixis

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam

Featured Video

17:33
AstraZeneca Oncology

First-line Maintenance Therapy for BRCAm Advanced Ovarian Cancer Fol…

Feat. S. Lewin
Breast
13:45
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Neoadjuvant Therapy in HR+ BC: Fulvestrant / Ful…

Feat. A. Bardia
11:45
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Adjuvant Therapy in BC: Is There a Long-term Ben…

Feat. A. Bardia
04:45
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on MBC: Does Early Local Therapy Improve Survival i…

Feat. A. Bardia
19:03
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ MBC: Comparing Efficacy of HER2 Kinase Inh…

Feat. I. Krop
14:46
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on TNBC & HR+ MBC: Analysis & Comparison of…

Feat. I. Krop
12:59
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on HER2+ Neoadjuvant BC: Which Pts Are Candidat…

Feat. R. L. Mahtani
15:17
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Adjuvant Therapy in HER2+ BC: Utilizing T-DM1 fo…

Feat. R. L. Mahtani
09:30
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ MBC: Tucatinib vs. TD-M1 vs. Neratinib - W…

Feat. R. L. Mahtani